Abstract. Angiogenesis plays critical roles in development, tumor growth and metastasis. Flufenamic acid (FFA) is an anti-inflammatory agent known to alter ion fluxes across the plasma membrane. Its role in angiogenesis has not been fully addressed to date. Here, we report that FFA treatment promotes angiogenesis both in vitro and in vivo. Applying FFA for 12 h promoted tube formation of human umbilical vein endothelial cells (HUVECs) without affecting cell proliferation. Three angiogenesis-related genes, VEGF, e-NOS and AAMP, were analyzed by RT-PCR. A significant difference was found between the FFA group and the control; the FFA group had significantly higher mRNA accumulation levels of all the three genes (p<0.05). Moreover, in the chick embryo chorioallantoic membrane (CAM) assay, FFA promoted the formation of macroscopic blood vessels. Finally, western blotting showed that the FFA-treated group had significantly higher phosphorylated AMPK levels, compared with the control (p<0.05). These results suggest that FFA promotes angiogenesis both in vitro and in vivo likely via promoting tube formation through AMPK activation.

Introduction

Angiogenesis, the formation of new blood vessels, plays important roles in the normal physiological situations, such as embryonic growth and wound healing (1,2). Angiogenesis also has profound impact on pathologic development, particularly on chronic inflammation (3). Evidence has been gathered regarding the association between angiogenesis and inflammation in pathologic conditions. These phenomena have long been coupled together in many chronic inflammation diseases including psoriasis, diabetes, Crohn's disease, rheumatoid arthritis and cancer (4-10). Many of the cells that play a role during inflammation release factors that have profound effects on vascular endothelial cells (11-14). On the other hand, angiogenesis sustains inflammation. Without angiogenesis, cells that present at inflammatory sites will be short of oxygen and nutrients to meet their metabolic needs (15). Thus, these two processes seem to depend on each other. Common molecular mechanisms have also been found to support this idea (16,17). According to this knowledge, direct therapeutic approaches against both chronic inflammation and angiogenesis will become our pursuit. Therefore, to further understand the cross-talk between inflammation and angiogenesis will be an important issue.

Fenamate belongs to a family of non-steroidal anti-inflammatory drugs (NSAIDs). One of the fenamates, flufenamic acid (FFA), is an inhibitor of cyclooxygenase (18) and has been shown to modulate several kinds of ion channels. FFA is commonly used as a blocker of non-selective cation current. It has been shown to inhibit the current of several members of TRP channel superfamily, to potentiate potassium current, to inhibit L-type calcium current, and to inhibit Ca\(^{2+}\)-dependent Cl\(^{-}\) current (19-23). The regulation of FFA on C-type TRP channels (TRPC) appears complex since FFA blocks currents of TRPC3 and TRPC7 channels whereas it potentiates the current of TRPC6 channels (24,25). Interestingly, both TRPC3 and TRPC6 have been shown to mediate vascular endothelial growth factor (VEGF)-induced current and TRPC6 also mediates VEGF-induced angiogenesis (26-28). Although FFA affected ion channels have been shown to be involved in angiogenesis, no report is available on the effect of this chemical on angiogenesis.

In the present study, we used HUVECs as a cell model of angiogenesis and the chicken CAM assay as an in vivo angiogenesis model. We investigated the effect of FFA on HUVECs proliferation and tube formation and its role in angiogenesis in chicken CAM.

Materials and methods

Materials. Flufenamic acid was purchased from Sigma-Aldrich (USA). BrdU monoclonal antibody was obtained from Neomarkers (USA). Texas-Red-conjugated goat anti-mouse...
secondary antibody was from Molecular Probes. Growth factor-free Matrigel was from BD Biosciences (USA). All cell culture media and reagents were obtained from Invitrogen (Carlsbad, CA, USA).

**Cell culture.** The HUVECs purchased from ScienCell (USA) were grown in ECM supplemented with 5% FBS, ECGs and PS in a humidified incubator with 5% CO₂ at 37°C. The cells were trypsinized with 0.15% trypsin-EDTA. Passages 3-10 were used for experiments.

**Proliferation assay.** Cell proliferation was determined by both counting the cell numbers and the BrdU incorporation assay. For counting the cell numbers, HUVECs were seeded at an initial density of 2x10⁴ per well in 6-well plates. The FFA was applied at a dose of 20, 50 and 100 µM. Cells were harvested and counted 24, 48 and 72 h after the treatment. Cell numbers were read in a Beckman Counter. For BrdU incorporation assay, 100 µM FFA was applied for 24 h. Then, cells were incubated in the medium with 10 µM BrdU for 3 h and stained with a monoclonal antibody against BrdU at 4°C for 12 h. A goat anti-mouse IgG labeled with Texas Red was used as secondary antibody. The results were expressed as the percentage of BrdU-positive cells over all the cells.

**Tube formation assay.** The Matrigel was applied to each well of a 24-well plate and incubated at 37°C for 60 min. The 6x10⁴ of endothelial cells was then seeded into each well with the medium containing 0.8% FCS with or without FFA (100 µM). Images of representative 10x fields were taken and endothelial cell tubes were quantified by counting length and branches.

**Western blot analysis.** The cells were washed twice with PBS and total cellular protein was then extracted in lysis buffer containing 62.5 mM Tris-HCl, 2% SDS, 10% glycerol with freshly added proteinase inhibitor cocktail (Sigma, Zwijndrecht, The Netherlands). The protein concentrations were determined by BCA assay (Pierce, Waltham, MA, USA). The protein lysates (40 µg/lane) were separated by SDS-PAGE and transferred onto nitrocellulose membranes. After blocking with 3% bovine serum albumin in phosphate-buffered saline, the membranes were incubated with antiphospho-AMPKα and-AMPKβ, or antiphospho-ACC antibody. After washing, the membranes were probed with horseradish peroxidase-conjugated anti-rabbit IgG and the bands were visualized using an ECL-Plus chemiluminescence detection system (GE Healthcare, NJ, USA). To confirm equal loading of proteins, the membranes were probed for β-actin protein.

**Reverse transcription polymerase chain reaction (RT-PCR).** HUVECs were lysed with TRIzol Reagent (Invitrogen) and total RNA was extracted according to the manufacturer's instructions. First-strand cDNA was synthesized from 1.5 µg of total RNA using Moloney murine leukemia virus reverse transcriptase (M-MLV RT) according to the manufacturer's instructions (Invitrogen). cDNA was amplified by PCR according to the manufacturer's instructions with Taq DNA polymerase (Invitrogen) under the following conditions: 94°C for 5 min, followed by 40 cycles of 94°C for 30 sec, 56°C for 30 sec and 72°C for 90 sec, with a final elongation step of 10 min at 72°C. The primer informations are as follows: VEGF: forward, 5'-CTACCTCCACATGCAAGT-3'; reverse, 5'-TTTCTTGCGCTTGTGGTGT-3'; GAPDH: forward, 5'-GGCTCTCCCTCTTCCGGCTG-3'; reverse, 5'-TAGCCGACGACGCCCT-3'; AAMP: forward, 5'-AGCCACTGCTGTGCTTTTAAG-3'; reverse, 5'-CCAAAACCAATGATCTCATCC-3'. The products were electrophoresed in 2% agarose gel and stained with ethidium bromide.

**Angiogenesis in chick embryo CAM.** Angiogenesis was assayed using the chick embryo CAM assay according to the method described previously (29). Briefly, fertilized chicken eggs were treated with ethanol (70%) and then incubated at 37°C. On day 3, 2-3-ml albumen was aspirated at the acute pole using a sterile 25-G hypodermic needle in order to allow detachment of the developing CAM from the eggshell. After the removal of albumen, we cut a square window ~10x10 mm into the shell and sealed the window with transparent tapes. Eggs were then incubated in a horizontal position. Six days later, we opened the window and implanted a 1-mm³ sterilized gelatin sponge containing DMSO or FFA onto the CAM. On day 12, the embryos of CAM were fixed by Bouin's fluid and the distribution and density of CAM vessels next to the site of grafting were analyzed.

**Statistical analyses.** All experiments were repeated three times independently. Data were presented as mean ± SEM. or as percentage of control. Statistical comparisons between groups were performed using the Student's t-test. p<0.05 was considered statistically significant.

**Results**

**FFA suppressed HUVEC growth.** To test whether FFA plays a role in angiogenesis, we first investigated the effect of FFA on HUVEC growth. The cells were incubated with DMSO, 20, 50 and 100 µM FFA for 24, 48 and 72 h before the cell numbers were determined. As shown in Fig. 1, FFA at the concentration of 20 µM had no effect on HUVEC growth at any time-point. FFA at the concentration of 50 µM had weak effect on HUVEC growth. The cell number was slightly reduced at the concentration of 50 µM after 72 h, however, there was no significant difference compared with DMSO control. When 100 µM FFA was applied to HUVEC, the numbers of the HUVEC started to reduce after 48 h and was greatly reduced after 72 h. No apoptosis was found at this concentration (data not shown).

**FFA reduced HUVEC proliferation.** It has been reported that FFA inhibits cell proliferation in other cell types (30-32). We next determined whether the effect of FFA on HUVEC cell number was due to its influence on cell proliferation. To address this question, we applied the BrdU incorporation assay. HUVECs were treated with 100 µM FFA for 24 h before they were incubated with 10 µM BrdU for another 3 h. BrdU is an analog of DNA precursor thymidine. When cells are proliferating, BrdU can be incorporated into DNA similarly to thymidine. In this way, the amount of the BrdU in
the cells reflects the proliferation rate of the cells. As shown in Fig. 2, the percentage of BrdU-positive cell in DMSO and FFA-treated group was 12±0.86 and 8.65±0.49%, respectively. There was a significant reduction of the percentage of BrdU-positive cells in the FFA treatment group compared with the control group (p<0.05).

**FFA promoted tube formation of HUVECs.** In vitro assays of tube formation using endothelial cells are commonly used to study critical steps of angiogenesis (33). We then examine the effect of FFA on tube formation using HUVECs cultured on Matrigel. The tube-like structure appeared 12 h after the HUVECs were seeded. The total tube length and the number of branching points were analyzed as indexes of angiogenesis.

We applied FFA to HUVECs when they were seeded on Matrigel. As shown in Fig. 3A, after 12 h, FFA greatly increased the formation of tube structure. Both total tube length and branching points were significantly increased in FFA treatment group. The relative total tube length of FFA-treated group increased 50.4% compared with that of control group (Fig. 3B). The average branching points per field of FFA-treated group increased 135% compared with that of control group (Fig. 3C). Together, these results suggest that FFA promotes angiogenesis without promoting endothelial cell proliferation.

**FFA induced AMPK activation.** FFA is one of the Nary-anthranilic acid derivatives, belonging to the fenamate group of NSAIDs (34). To examine whether FFA regulates angiogenesis through AMPK activation, phospho-AMPKα and-AMPKβ and phospho-ACC were measured by western
Ge et al.: Flufenamic Acid Promotes Angiogenesis

Blotting. As shown in Fig. 4, incubation of HUVECs with FFA resulted in increased levels of phosphorylated AMPKα and AMPKβ, which was associated with paralleled elevation of phosphorylated ACC, one of the AMPK substrates (35). Compared with control, FFA-treated group had significantly higher phosphorylated AMPK levels (p<0.05).

Expression of angiogenesis markers. Vascular endothelial growth factor (VEGF), endothelial NO synthase (e-NOS), the angio-associated migratory cell protein (AAMP) are three angiogenesis related genes, which were strongly expressed in endothelial cells (36). The mRNA levels of VEGF, e-NOS and AAMP were measured by RT-PCR. Expression of all three angiogenesis related genes is shown in Fig. 5. There was a significant difference between FFA group and control, FFA group had a significantly higher mRNA accumulation level of all the three angiogenesis related genes (p<0.05).

The effect of FFA on angiogenesis in vivo. We further examined the possible effect of FFA on angiogenesis in vivo. In order to explore the role of FFA in vivo, we applied the chicken chorioallantoic membrane (CAM) assay. We implanted a 1-mm³ sterilized gelatin sponge which contained PBS or FFA onto the chorioallantoic membrane for ~72 h for the blood vessel to grow into the sponge. Then the sponge was fixed and the distribution and density of CAM vessels next to the site of grafting were analyzed.

As shown in Fig. 6, the vessel density in the CAM implanted with the gelatin sponge containing PBS was 15.99±1.30. The vessel density in the CAM implanted with the gelatin sponge containing FFA was 23.74±1.82, which was a significant increase compared with the control group. These results suggest that FFA promotes angiogenesis in vivo.

Discussion

Our results indicate that FFA treatment promotes angiogenesis. In the tube formation assay of HUVEC cells, both total tube length and the number of branching points were increased in the FFA treatment group compared to the control group and cell proliferation was not significantly affected at the time when tube formation assay was performed. AMP-activated protein kinase (AMPK) is a key regulator of metabolic homeostasis (35) and has anti-inflammatory effects (37,38).

In addition, it promotes angiogenesis, and protects cells from apoptosis (39-41). RT-PCR was used to analyse the expression of VEGF, AAMP, e-NOS and the results showed significantly increased expression in response to FFA-stimulation. These results indicated that FFA promoted angiogenesis in vitro.
Moreover, FFA can also promote angiogenesis in vivo. In the chicken CAM assay FFA significantly increased the number of vessels that grow into the gelatin sponge. In addition, we observed that FFA can significantly increase the phosphorylated levels of AMPK. Our results thus support the notion that FFA promotes angiogenesis both in vitro and in vivo through AMPK activation.

The process of angiogenesis includes the proliferation of endothelial cells and migration of these cells to form tube-like structures. At the concentration of 100 μM, 12-h FFA treatment did not affect HUVEC proliferation whereas promoted the formation of tube-like structures and it was not until 24 h that FFA treatment began to inhibit cell proliferation. The differential effect of FFA on tube formation and cell proliferation is probably due to the multiple targets of FFA. FFA has been reported to inhibit cell proliferation in several cell types (30,42). As a non-selective cation blocker, FFA blocks several channels that have been shown to be involved in the process of cell proliferation. For example, TRPM7 is required for MCF-7 cell proliferation (43). TRPC3 has been shown to be necessary for proliferation of SKOV3 cells (44). Whether the effect of FFA on HUVEC proliferation is the result of its inhibitory effect on these channels remains uncertain. The way FFA promotes HUVEC tube formation is probably through its other targets. For instance, FFA-potentiated non-selective cation channel is required for lysophosphatidylcholine-induced monocyte migration (45). FFA can potentiate the current of TRPC6 and TRPC6 has been shown to promote HUVECs tube formation (28). It is thus possible that TRPC6 participates in FFA-induced tube formation.

Common molecular mechanisms have already been shown to regulate both chronic inflammation and angiogenesis (46,47). These two processes seem to depend on each other based on literature (3,48). However, as an anti-inflammatory agent, FFA promotes angiogenesis in our system. Therefore, a careful understanding of the cross-talk between angiogenesis and chronic inflammation is very important for more effective therapies.

In conclusion, our data show that FFA treatment promotes HUVEC tube formation in vitro. In the in vivo experiment using chick CAM assay, FFA also promotes vessels to grow into the gelatin sponge. Moreover, the phosphorylated AMPK levels were significantly higher in FFA-treated group. These data suggest that FFA promotes angiogenesis both in vitro and in vivo.

References


